LCL124, a cationic analog of ceramide, selectively induces pancreatic cancer cell death by accumulating in mitochondria

Journal of Pharmacology and Experimental Therapeutics

Volumn 344, Issue 1, 2013, Pages 167-178

  Beckham, Thomas H ^a   Lu, Ping ^a   Jones, Elizabeth E ^a   Marrison, Tucker ^a   Lewis, Clayton S ^c   Cheng, Joseph C ^a   Ramshesh, Venkat K ^c   Beeson, Gyda ^b   Beeson, Craig C ^b   Drake, Richard R ^a   Bielawska, Alicja ^a   Bielawski, Jacek ^a   Szulc, Zdzislaw M ^a   Ogretmen, Besim ^a   Norris, James S ^a   Liu, Xiang ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE DERIVATIVE; CISPLATIN; CYTOCHROME C; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; LCL 124; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DEPOLARIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; ENZYME RELEASE; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR XENOGRAFT;

EID: 84871709091     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.112.199216     Document Type: Article

References (57)

1. Aronov O, Horowitz AT, Gabizon A, Fuertes MA, Pérez JM, and Gibson D (2004) Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues. Bioconjug Chem 15:814-823. (Pubitemid 38981956)
2. Arora AS, Jones BJ, Patel TC, Bronk SF, and Gores GJ (1997) Ceramide induces hepatocyte cell death through disruption of mitochondrial function in the rat. Hepatology 25:958-963. (Pubitemid 27157141)
3. Bai J, Sui J, Demirjian A, Vollmer CM, Jr, Marasco W, and Callery MP (2005) Predominant Bcl-XL knockdown disables antiapoptotic mechanisms: tumor necrosis factor-related apoptosis-inducing ligand-based triple chemotherapy overcomes chemoresistance in pancreatic cancer cells in vitro. Cancer Res 65:2344-2352. (Pubitemid 40490145)
4. Beckham TH, Elojeimy S, Cheng JC, Turner LS, Hoffman SR, Norris JS, and Liu X (2010) Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets 14:529-539.
5. Beeson CC, Beeson GC, and Schnellmann RG (2010) A high-throughput respirometric assay for mitochondrial biogenesis and toxicity. Anal Biochem 404:75-81.
6. Bielawska A, Bielawski J, and Szulc ZM, et al. (2008) Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem 16:1032-1045. (Pubitemid 351163040)
7. Bielawski J, Szulc ZM, Hannun YA, and Bielawska A (2006) Simultaneous quantitative analysis of bioactive sphingolipids by high-performance liquid chromatography-tandem mass spectrometry. Methods 39:82-91. (Pubitemid 44107706)
8. Van Blerkom J, Davis P, and Alexander S (2003) Inner mitochondrial membrane potential (DeltaPsim), cytoplasmic ATP content and free Ca2+ levels in metaphase II mouse oocytes. Hum Reprod 18:2429-2440. (Pubitemid 37427827)
9. Bold RJ, Chandra J, and McConkey DJ (1999) Gemcitabine-induced programmed cell death (apoptosis) of human pancreatic carcinoma is determined by Bcl-2 content. Ann Surg Oncol 6:279-285. (Pubitemid 29221014)
10. Burris HA, 3rd, Moore MJ, and Andersen J, et al. (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403-2413. (Pubitemid 27251144)
11. Chen LB (1988) Mitochondrial membrane potential in living cells. Annu Rev Cell Biol 4:155-181.
12. Chmura SJ, Nodzenski E, Beckett MA, Kufe DW, Quintans J, and Weichselbaum RR (1997) Loss of ceramide production confers resistance to radiation-induced apoptosis. Cancer Res 57:1270-1275. (Pubitemid 27152550)
13. Conroy T, Desseigne F, and Ychou M, et al.; Groupe Tumeurs Digestives of Unicancer;; PRODIGE Intergroup (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825.
14. Cornett DS, Frappier SL, and Caprioli RM (2008) MALDI-FTICR imaging mass spectrometry of drugs and metabolites in tissue. Anal Chem 80:5648-5653.
15. Dahm F, Bielawska A, Nocito A, Georgiev P, Szulc ZM, Bielawski J, Jochum W, Dindo D, Hannun YA, and Clavien PA (2008) Mitochondrially targeted ceramide LCL-30 inhibits colorectal cancer in mice. Br J Cancer 98:98-105.
16. Dang CV (2010) Rethinking the Warburg effect with Myc micromanaging glutamine metabolism. Cancer Res 70:859-862.
17. Fowler JD, Brown JA, Johnson KA, and Suo Z (2008) Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase. J Biol Chem 283:15339-15348.
18. Friess H, Lu Z, Andrén-Sandberg A, Berberat P, Zimmermann A, Adler G, Schmid R, and Büchler MW (1998) Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer. Ann Surg 228:780-787. (Pubitemid 30191689)
19. García JJ, Ogilvie I, Robinson BH, and Capaldi RA (2000) Structure, functioning, and assembly of the ATP synthase in cells from patients with the T8993G mitochondrial DNA mutation. Comparison with the enzyme in Rho(0) cells completely lacking mtdna. J Biol Chem 275:11075-11081. (Pubitemid 30212749)
20. Guillermet-Guibert J, Davenne L, Pchejetski D, Saint-Laurent N, Brizuela L, Guilbeau-Frugier C, Delisle MB, Cuvillier O, Susini C, and Bousquet C (2009) Targeting the sphingolipid metabolism to defeat pancreatic cancer cell resistance to the chemotherapeutic gemcitabine drug. Mol Cancer Ther 8:809-820.
21. Han H, Bearss DJ, Browne LW, Calaluce R, Nagle RB, and Von Hoff DD (2002) Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. Cancer Res 62:2890-2896. (Pubitemid 34525776)
22. Holland WL, Brozinick JT, and Wang L-P, et al. (2007) Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 5:167-179.
23. Hussain S-RA, Lucas DM, and Johnson AJ, et al. (2008) Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium. Blood 111:3190-3199.
24. Huwiler A and Zangemeister-Wittke U (2007) Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol 63:150-159. (Pubitemid 46990918)
25. Jaffee EM, Hruban RH, Canto M, and Kern SE (2002) Focus on pancreas cancer. Cancer Cell 2:25-28. (Pubitemid 41043985)
26. Kim JW and Dang CV (2006) Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 66:8927-8930.
27. King MP and Attardi G (1989) Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science 246:500-503. (Pubitemid 19273941)
28. Lee H-C and Wei Y-H (2005) Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. The International Journal of Biochemistry Cell Biology 37:822-834. (Pubitemid 40203003)
29. Lee KM, Yasuda H, Hollingsworth MA, and Ouellette MM (2005) Notch 2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest 85:1003-1012. (Pubitemid 41486425)
30. Lemasters JJ and Ramshesh VK (2007) Imaging of mitochondrial polarization and depolarization with cationic fluorophores. Methods Cell Biol 80:283-295.
31. Lin CF, Chen CL, Chang WT, Jan MS, Hsu LJ, Wu RH, Fang YT, Tang MJ, Chang WC, and Lin YS (2005) Bcl-2 rescues ceramide- and etoposide-induced mitochondrial apoptosis through blockage of caspase-2 activation. J Biol Chem 280:23758-23765.
32. Lin CF, Chen CL, Chiang CW, Jan MS, Huang WC, and Lin YS (2007) GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J Cell Sci 120:2935-2943.
33. Liu X, Cheng JC, Turner LS, Elojeimy S, Beckham TH, Bielawska A, Keane TE, Hannun YA, and Norris JS (2009) Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets 13:1449-1458.
34. Liu X, Elojeimy S, and Turner LS, et al. (2008) Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci 13:2293-2298. (Pubitemid 351589254)
35. Mini E, Nobili S, Caciagli B, Landini I, and Mazzei T (2006) Cellular pharmacology of gemcitabine. Ann Oncol 17 (Suppl 5):v7-v12. (Pubitemid 43994854)
36. Mitchell P and Moyle J (1967) Chemiosmotic hypothesis of oxidative phosphorylation. Nature 213:137-139.
37. Modica-Napolitano JS and Aprille JR (2001) Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49:63-70. (Pubitemid 32493800)
38. Modrak DE, Cardillo TM, Newsome GA, Goldenberg DM, and Gold DV (2004) Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res 64:8405-8410. (Pubitemid 39491780)
39. Modrak DE, Gold DV, and Goldenberg DM (2006) Sphingolipid targets in cancer therapy, Mol Cancer Ther 5 (2):200-208.
40. Modrak DE, Leon E, Goldenberg DM, and Gold DV (2009) Ceramide regulates gemcitabine-induced senescence and apoptosis in human pancreatic cancer cell lines. Mol Cancer Res 7:890-896.
41. Nilsson A, Fehniger TE, Gustavsson L, Andersson M, Kenne K, Marko-Varga G, and Andrén PE (2010) Fine mapping the spatial distribution and concentration of unlabeled drugs within tissue micro-compartments using imaging mass spectrometry. PLoS ONE 5:e11411.
42. Novgorodov SA, Szulc ZM, Luberto C, Jones JA, Bielawski J, Bielawska A, Hannun YA, and Obeid LM (2005) Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J Biol Chem 280:16096-16105. (Pubitemid 40616734)
43. Oberstein PE and Saif MW (2011) First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium".San Francisco, CA, USA. January 20-22, 2011. JOP 12:96-100.
44. Ogretmen B and Hannun YA (2004) Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 4:604-616. (Pubitemid 39025055)
45. Pilkington GJ, Parker K, and Murray SA (2008) Approaches to mitochondrially mediated cancer therapy. Semin Cancer Biol 18:226-235.
46. Rao S and Cunningham D (2002) Advanced pancreatic cancer - 5 years on. Ann Oncol 13:1165-1168. (Pubitemid 34960122)
47. Rossi MJ, Sundararaj K, Koybasi S, Phillips MS, Szulc ZM, Bielawska A, Day TA, Obeid LM, Hannun YA, and Ogretmen B (2005) Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol Head Neck Surg 132:55-62. (Pubitemid 40052672)
48. Schniewind B, Christgen M, Kurdow R, Haye S, Kremer B, Kalthoff H, and Ungefroren H (2004) Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer 109:182-188. (Pubitemid 38240918)
49. Senkal CE, Ponnusamy S, and Rossi MJ, et al. (2006) Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J Pharmacol Exp Ther 317:1188-1199. (Pubitemid 43764124)
50. Shi X, Liu S, Kleeff J, Friess H, and Büchler MW (2002) Acquired resistance of pancreatic cancer cells towards 5-Fluorouracil and gemcitabine is associated with altered expression of apoptosis-regulating genes. Oncology 62:354-362. (Pubitemid 34914105)
51. Stoica BA, Movsesyan VA, Knoblach SM, and Faden AI (2005) Ceramide induces neuronal apoptosis through mitogen-activated protein kinases and causes release of multiple mitochondrial proteins. Mol Cell Neurosci 29:355-371. (Pubitemid 40799209)
52. Szulc ZM, Bielawski J, Gracz H, Gustilo M, Mayroo N, Hannun YA, Obeid LM, and Bielawska A (2006) Tailoring structure-function and targeting properties of ceramides by site-specific cationization. Bioorg Med Chem 14:7083-7104. (Pubitemid 44403118)
53. Van Cutsem E, Aerts R, Haustermans K, Topal B, Van Steenbergen W, and Verslype C (2004) Systemic treatment of pancreatic cancer. Eur J Gastroenterol Hepatol 16:265-274. (Pubitemid 38368369)
54. Xu ZW, Friess H, Büchler MW, and Solioz M (2002) Overexpression of Bax sensitizes human pancreatic cancer cells to apoptosis induced by chemotherapeutic agents. Cancer Chemother Pharmacol 49:504-510. (Pubitemid 34671287)
55. Yu T, Li J, and Sun H (2010) C6 ceramide potentiates curcumin-induced cell death and apoptosis in melanoma cell lines in vitro. Cancer Chemother Pharmacol 66:999-1003.
56. Yu XJ, Long J, Fu DL, Zhang QH, and Ni QX (2003) Analysis of gene expression profiles in pancreatic carcinoma by using cDNA microarray. Hepatobiliary Pancreat Dis Int 2:467-470. (Pubitemid 37069624)
57. Zhu C, Johansson M, and Karlsson A (2000) Incorporation of nucleoside analogs into nuclear or mitochondrial DNA is determined by the intracellular phosphorylation site. J Biol Chem 275:26727-26731.